Kornimate/medical-research-clean huggingface dataset:
a phase iv study of the onset and maintenance of the antiplatelet effect of ticagrelor compared with clopidogrel in chinese patients with acs

Conditions: Non-ST or ST Elevation Acute Coronary Syndromes

Summary: the purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in chinese patients with acs.


Eligibility criteria:
inclusion criteria: * 1. provision of informed consent prior to any study specific procedures * 2. female or male aged at least 18 years * 3. females of child-bearing potential must have a negative urine pregnancy test at enrolment and be willing to use reliable contraception * 4. index event of non-st or st segment elevation acs. exclusion criteria: * 1.contraindication or other reason that clopidogrel or ticagrelor should not be administered (eg, hypersensitivity, active bleeding, moderate or severe liver disease, history of previous intracranial bleed, gi bleed within the past 6 months, major surgery within 30 days) * 2. oral anticoagulation therapy or gp iib/iiia receptor antagonists therapy within 30 days prior to randomisation or cannot be stopped * 3. ticagrelor or clopidogrel or other p2y12 inhibitors within 14 days prior to randomisation * 4. requires dialysis * 5. nonselective non-steroidal anti-inflammatory drugs (nsaids) and prostacyclins (pgi2) therapy that cannot be stopped

Keywords: non-st or st elevation acute coronary syndromes, ticagrelor, clopidogrel, antiplatelet effect
factors involved in obesity-related inflammation and insulin resistance

Conditions: Obesity; Insulin Resistance; Inflammation

Summary: in this project, we propose to recruit lean and obese subjects with different ethnic background (african americans and caucasians) to study the alterations of lipid and carbohydrate metabolism and determine whether these disturbances are linked to genetic, inflammatory, oxidative stress, and/or nutritional factors. because systemic inflammation and insulin resistance are frequent features of obesity, we postulate that an unbalanced diet with high saturated- and low omega 3-fatty acids is linked to obesity-related inflammation and insulin resistance. we propose to investigate fatty acid metabolism and determine the links between fatty acid composition and oxidative stress in tissues of lean and obese subjects. we propose the following aims: specific aim 1: evaluate nutrient intake in lean and obese subjects using the standard nhanes food questionnaire. specific aim 2: evaluate the fatty acid composition, including omega-3, in adipose tissue depots, blood monocytes and skeletal muscle, and examine the relationship between omega-3 content and inflammatory and oxidative stress markers. specific aim 3: compare the effects of omega-3 and saturated fa supplementation on inflammatory and oxidative stress markers in vitro in adipose tissue explants, preadipocytes and monocyte culture.


Eligibility criteria:
inclusion criteria: * 18-65 years of age * undergoing elective abdominal or bariatric surgery exclusion criteria: * intercurrent infections * active cancer diagnosis within 5 years * use of medications for diabetes or hyperlipidemia * use of glucocorticoids or anti-inflammatory drugs

Keywords: obesity insulin resistance inflammation
the effect of kinesio taping® on motor control in patients with patellofemoral pain syndrome

Conditions: Knee Injuries; Pain Syndrome

Summary: background: recently, several professionals are using the kinesio taping® in the treatment of pathologies related to the knee, aiming to improve the motor control, increase the response of muscle activation and promoting better joint stability. purpose: the objective of this study is to evaluate the effect of the application of kinesio taping® in motor control of patients with patellofemoral pain syndrome. methods: this is a 2-arm, randomized with a blinded assessor. we selected 40 women with patellofemoral pain (age 25.2±4,years) were randomly assigned to one of two groups: placebo group (n= 20) and the kinesio taping® group (n=20). the placebo group received the application of a non-stretchable tape (micropore) crosswise on the thigh and the kinesio taping® group followed all the criteria of the method in placing the bandage. all patients received the evaluation of the motor control banding pre and post a patch, by means of the method y balance test.


Eligibility criteria:
inclusion criteria: * patellofemoral pain syndrome diagnoses * aged 18-40 years * kujala questionnaire above exclusion criteria: * neurological disorders * bmi indicating obesity (bmi\> 30kg / m²) * high-performance athletes * history of surgeries in lower limbs * in treatment of any underlying pathology
evaluating the safety, tolerability, and efficacy of gs-9674 in participants with nonalcoholic steatohepatitis (nash)

Conditions: Nonalcoholic Steatohepatitis (NASH)

Summary: the primary objective of this study is to evaluate the safety and tolerability of gs-9674 in participants with nonalcoholic steatohepatitis (nash).


Eligibility criteria:
key inclusion criteria: * meets the following conditions: * a clinical diagnosis of nonalcoholic fatty liver disease (nafld) * screening magnetic resonance imaging - proton density fat fraction (mri-pdff) with ≥ 8% steatosis * screening magnetic resonance elastography (mre) with liver stiffness ≥ 2.5 kilopascal (kpa) or * a historical liver biopsy within 12 months of screening consistent with nash with fibrosis, but not cirrhosis, and * no documented weight loss \> 5% between the date of the liver biopsy and screening. * platelet count ≥ 150,000/mm\^3 * albumin ≥ 3.3 g/dl * serum creatinine ≤ upper limit of normal (uln) key exclusion criteria: * pregnant or lactating females * alanine aminotransferase (alt) \> 5x upper limit of the normal range (uln) * other causes of liver disease including autoimmune, viral, and alcoholic liver disease * cirrhosis of the liver * prior history of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding * body mass index (bmi) \< 18 kg/m\^2 * uncontrolled diabetes mellitus (hemoglobin a1c \> 9% at screening) * international normalized ratio (inr) \> 1.2 unless on anticoagulant therapy * total bilirubin \> 1 x uln, except with diagnosis of gilbert's syndrome note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: non-alcoholic fatty liver disease (nafld) fibrosis gs-9674
study of adjuvant ono-4538 with resected gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with nivolumab in combination with tegafur-gimeracil-oteracil potassium (s-1 therapy) or capecitabine + oxaliplatin (capeox therapy), in comparison with placebo in combination with s-1 therapy or capeox therapy, in pstage iii gastric cancer (including esophagogastric junction cancer) after d2 or more extensive lymph node dissection.


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed adenocarcinoma of the stomach * patients without a remnant cancer (r0) who have undergone gastrectomy * gastric carcinoma according to the stage classification of ajcc/uicc tnm classification, 7th edition on the basis of overall postoperative findings * eastern cooperative oncology group (ecog) performance status (ps) score of 0 or 1 exclusion criteria: * patients who have received non-surgical treatment (e.g., radiotherapy, chemotherapy, hormone therapy) for gastric cancer * multiple primary cancers * a current or past history of severe hypersensitivity to any other antibody products * any concurrent autoimmune disease or past history of chronic or recurrent autoimmune disease

Keywords: ono-4538,bms-936558,nivolumab,gastric,adjuvant,s-1,capeox
comparison of suv using spect/ct between grave's disease patients and normal humans

Conditions: Hyperthyroidism; Tomography; Emission-Computed; Single-Photon

Summary: the purpose of this study is to find out the capacity of standardized uptake value (suv) using single-photo emission computed tomography and computed tomography (spect/ct) in diagnosing grave's disease (hyperthyroidism).

traditionally it is considered that only positron emission tomography(pet) has the ability to obtain standardized uptake value（suv）while single-photo emission computed tomography(spect) does not have. recently with the developing of technology, the ability of spect has been extended. on the other hand, thyroid imaging by spect can only play an auxiliary role in hyperthyroidism diagnosis mainly since it is regarded as nonquantitative. so the investigators design this study to search the capacity and accuracy of suv provided by spect and ct(ct is used for reconstruction algorithm) in diagnosing gd. this is a multiple-center study containing nine groups in china that use ge discovery nm/ct, an advanced equipment. thus, the data can be more accurate and more available. and this is a perspective clinical trial, taking about eight months. the investigators plan to evaluate at least 50 grave's disease(gd) patients and 50 normal humans as contrast in all. every gd patient must have been diagnosed and the results of thyroid function tests(such as tsh,ft3,ft4） must be available. if necessary, the patient's rate of iodine uptake should also be known before he/she being included in this study. as for normal people, the results of thyroid function tests should be within the range of normal value. the data of each participant will be gathered and stored. and the data processing will be done with the help of ge staff, using the software q.metrix to get the value of suvmean, suvmax. finally t test will be used in comparison of the differences.

Eligibility criteria:
for group of gd patients: inclusion criteria: * certainly diagnosed with gd * no treatment * sign a informed consent exclusion criteria: * inflammatory hyperthyroidism * secondary hyperthyroidism (since of medicine, thyrotrophs neoplasms and etc) * can not finish the check of spect/ct * refuse to sign a informed consent for group of normal humans: inclusion criteria: * without gd * adult * sign a reformed consent exclusion criteria: * without normal values of tsh, ft3, ft4 * can not finish the check of spect/ct * failed to sign a reformed consent

Keywords: standardized uptake value diagnosis
transoral versus transbuccal placement of bicortical screws during orthognathic surgery

Conditions: Prognathism; Retrognathia; Jaw Abnormalities

Summary: bicortical screws have been widely used for mandibular osteosynthesis during orthognathic surgery.transoral placement of bicortical screws is a rigid fixation method in orthognathic surgery, which is less often used. the aim of this study was to compare postoperative outcome of transoral versus transbuccal bicortical screw placement during orthognathic surgery. this study comprises an academic, retrospective, monocentric study in which the charts of orthognathic patients operated between january 2010 and december 2012 were retrospectively reviewed. postoperative complications were registered. demographic, dental and surgical parameters are examined as potential risk factors for the occurence of postoperative complications.


Eligibility criteria:
inclusion criteria: * patients of all ages * patients of all genders * patients who had undergone a bimaxillary osteotomy, a bilateral sagittal split ramus osteotomy (bsso), a bsso with a chin osteotomy or a trimaxillary osteotomy exclusion criteria: * patients where cement had been used at the osteotomy sites * patients who had undergone a multisegmented mandibular osteotomy * patients who had undergone an osteosynthesis with plates * patients where the postoperative orthopantomogram was unavailable * patients where data regarding the type of screw placement was unavailable

Keywords: transoral approach transbuccal approach postoperative complications
virtual reality alcohol avoidance training

Conditions: Alcohol Use Disorder

Summary: the approach-avoidance training program (aatp) has shown preliminary promise as an add-on to standard treatment for alcohol dependence. however, knowledge is lacking as to whether the effectiveness of aatp can be enhanced further when performed in a typical drinking situation. the main aim of this study is to investigate whether approach-avoidance training implemented in a virtual reality bar environment is superior to the classical joystick pc-version of the aatp.

the study will be implemented as a randomized controlled trial. a total of 135 consecutively enrolled alcohol use disorder (aud) patients, recruited from alcohol inpatient clinics in germany, poland and denmark, will be randomized into one of three groups at the start of standard alcohol treatment: group a) stimuli-relevant aatp as usual; group b) stimuli-relevant attp in virtual reality, and group c) treatment as usual (tau; control group). treatment outcomes will be assessed at pre-treatment, post-treatment and 3-month follow-up. generalized mixed-models will be applied to compare the trajectories of the groups over time on drinking, craving and impulsiveness outcomes.

Eligibility criteria:
inclusion criteria: * signed written informed consent * meeting the diagnostic criteria for alcohol use disorder * fluent in language of the participating country (german, polish or danish) * completion of detoxification (if needed) * enrolled in standard treatment within two weeks exclusion criteria: * any sensory or motor deficits complicating the provision of the aat (e.g. color-blindness, fine or gross motor deficits in upper extremities) * meeting diagnostic criteria for other substance use disorders * severe psychiatric or neurological illness (e.g. psychotic disorders, mental retardation, dementia) or terminal somatic illness

Keywords: approach bias virtual reality training
effect of neutralization of endogenous acid production on bmd and bone microarchitectural

Conditions: Healthy

Summary: hypothesis: neutralization of acid production induced by the western diet with oral administration of potassium citrate increases bone mineral density and bone mass as well as skeletal muscle mass and strength in elderly people (\> 65y).

we will perform a prospective, randomized, placebo-controlled trial evaluating the effect of k citrate on bone mineral density, microarchitectural composition of bone,nutritional parameters, lean body mass, parameters of skeletal muscle mass and strength, 24h and exercise induced blood pressure changes in otherwise healthy, elderly ambulatory subjects of both genders. potassium citrate (60 meq) is supplied as tablets with a wax matrix (10 meq of citrate per tablet) and ingested in three doses/day. all subjects will receive daily oral 500 mg of calcium and 400 iu of vitamin d to ensure adequate calcium and vitamin d supply.

Eligibility criteria:
inclusion criteria: * men and women, 65 to 80y, tscores at l2-l4 0 to -2.5 exclusion criteria: * treated or necessity to treat low bmd (t-score l2 to l4 \<-2.5) * any major medical illness that would possibly need hospitalization and/or be followed by foreseeable complications within 12 months and/or have a life-expectancy of less than 5 years * stable serum creatinine \> 150 umol/l and/or known type iv renal-tubular acidosis (hyperkalemia) * vegetarians * concommitant drug prescriptions: systemic and topical glucocorticoids, systemically acting estrogens (topical allowed): both within the last 6 months. antiosteoporosis drugs: bisphosphoponates, fluoride, calcitonin, all within the previous 12 months. * vitamin d deficiency at screening visit * technical difficulties to delineate bone area of interest during the screening visit

Keywords: endogenous acid production metabolic acidosis potassium citrate osteoporosis sarcopenia hypertension effect of potassium citrate on bone mineral density and bone mass
uremic hyperhomocysteinemia -a folate trial for possible prevention of cardiovascular events

Conditions: Uremia; Chronic Renal Failure; Hemodialysis; Hyperhomocysteinemia; Cardiovascular Disease

Summary: homocysteine recently gained access to the category of risk factor for the development of atherosclerotic cardiovascular disease in the general population. chronic renal failure patients, even before being introduced to dialysis therapy have almost universal elevation of serum homocysteine; when on dialysis their mortality is above 50% related to cardiovascular disease that we might now speculate, with a contribution of potentially toxic levels of the aminoacid homocysteine.

we conducted a double blind , randomized, placebo controlled trial, for two years, enroling, simultaneously, 186 end-stage kidney disease patients of any cause, older than 18 years of age, stable on hemodialysis, assigned to receive either oral folic acid 10 mg three times a week on post dialysis sessions, under nurse supervision or an identical appearing placebo for the entire lenght of the study, from april 2003 to march 2005. the two groups had similar baseline clinical and laboratory characteristics. there was no loss of follow-up. at admission, homocysteine serum levels were above 13,9 umol/l in 96.7% (median 25.0, range 9.3-104.0)with only five cases in the normal levels; homocysteine remained elevated at 6, 12 and 24 months on those receiving placebo; folate treatment significantly decreased total homocysteine levels to a median value of 10.5 umol/l (2.8 - 20.3)which remained at this level for the entire study time (p\ 0.05)or other causes(15), after being included in the study. intima-media wall thickness blinded measured at the common carotid artery decreased from 1.94+-0,59 mm to 1.67+-0.38 (p\<0.001) with folate therapy and became thicker, from 1.86+-0.41 to 2.11+-0.48 mm in the placebo group. in conclusion, folate treatment for two years was not effective on modifying cardiovascular death and non fatal cardiovascular events of this sample population with chronic uremia; however, the ultrasonographic evaluation of the common carotid arteries intima-media wall thickness at entry and twenty four months later unequivocally showed a significant thickness decrease with supervised folate intake. earlier prescription of folic acid might benefit patients with chronic renal failure,preventing cardiovascular deterioration

Eligibility criteria:
inclusion criteria: * patients stable on hemodialysis for 4 months or more * eighteen years of age or older exclusion criteria: * potential kidney transplant from a living donor in the near future * severe cardiovascular disease * cancer and active inflammation

Keywords: hemodialysis chronic uremia hyperhomocysteinemia folate
effect of high volumehemodiafiltration on lung oxygenation

Conditions: Haemofiltration; Lung Mechanics; Septic Patients

Summary: high volume hemodiafiltration (hvhdf) has been used in septic patients to get hemodynamic improvement and possibly survival benefit.

sepsis, defined as life-threatening organ dysfunction caused by dysregulated immune response to infection. hemofiltration has been suggested as beneficial in restoring immune homeostasis. high volume hemodiafiltration (hvhdf) is a hybrid method of intermittent renal replacement therapy (rrt), where high filtration volumes are applied. in several studies; higher filtration volumes have been shown to achieve hemodynamic improvement and possibly survival benefit in patients with septic shock.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years 2. severe sepsis defined by quick sofa score by presentation of 2 or more of the following criteria: * mental clouding: decreased glasco coma scale gcs \< 15 * hypotension: systolic blood pressure \< 100 mmgh * tachypnea: respiratory rate \> 22 breath/ minute then serum lactate is analysed to confirm sepsis hypoperfusion if ≥ 2mmol/l 3. organs dysfunction (including one of them respiratory failure). organ dysfunctions are defined as following: respiratory dysfunction (criteria for ards): * pao2/fio2 \<200 * bilateral infiltrates in chest x-ray * resistant hypoxemia * tachypnoea (rr \> 40 breath/minute) * the need for invasive mechanical ventilation * excluded cardiac causes of pulmonary edema cns failure: * decreased gcs ≥ 4 decreased points cvs dysfunction: * sustained hypotension even on very high inotropes doses (noradrenaline \>1µm/min)+ adrenaline\>1.5µm/min associated * with high cvp pressure \> 12 mmhg and not responding to fluid challenge test to exclude hypovolemia. * cardiomegaly detected by either echocardiography assessment, or chest x-ray * resistant frequent ventricular ectopics not explained by organic causes. liver dysfunction: * elevated total and direct bilirubin than double normal or basal levels * elevated prothrombin time \> 17 seconds or inr \> 1.5 * elevated liver enzymes \> triple normal level renal dysfunction: * decreased urine output \< 0.5 ml/kg. * elevated creatinine level \> 164 µmol/l (1.5mg/dl). * decreased creatinine clearance \<50ml/minute if available. bone marrow depression: * decreased platelets \< 90 x 103/µl * decreased leukocytes \<4 x 103/µl * decreased rbcs count \< 4 x 106/µl exclusion criteria: 1. patient relatives' refusal 2. pregnancy 3. recent active internal hemorrhage 4. not mechanically ventilated. 5. hypersensitivity to the dialyser fluid
differences in frail and non-frail critically-ill patients in functional outcomes

Conditions: Critical Care; Rehabilitation; Outcome Assessment; Critical Illness; Frailty; Physical and Rehabilitation Medicine; Exercise Therapy; Intensive Care Unit

Summary: this is a prospective analysis of patient registry data of intensive care patients. the aim is to investigate if frailty is a predictor of decline of functional status of critically ill patients during their hospital stay.

elderly critical-ill patients with a high frailty level are becoming increasingly important in the icu and the health system. especially, questions about the course of the individual proceeding, withhold of therapy and level of care are controversial among caretakers, as outcome and functional independence remain still unclear in these patients. this applies particularly in view of the fact that large studies such as vip1 showed an inverse association of high frailty classes with short-term survival. our main objective in this study was to focus on functional outcome and independency measured by barthel index after icu stay regarding frailty, the effect of critical care and severity and prognosis of the disease.

Eligibility criteria:
inclusion criteria: * intensive care stay \> 48 hours exclusion criteria: * none

Keywords: early mobilization early rehabilitation functional status functional outcome patient outcome intensive care critical care outcomes